OS Therapies’ (OSTX) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of OS Therapies (NYSE:OSTX) in a report released on Tuesday,Benzinga reports. They currently have a $20.00 price target on the stock.

A number of other equities research analysts have also weighed in on OSTX. Lake Street Capital began coverage on OS Therapies in a research report on Wednesday, April 2nd. They set a “buy” rating and a $19.00 target price on the stock. Maxim Group upped their price objective on OS Therapies from $8.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, January 16th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, OS Therapies has an average rating of “Buy” and a consensus price target of $18.00.

OS Therapies Stock Performance

OSTX stock opened at $1.59 on Tuesday. OS Therapies has a one year low of $1.12 and a one year high of $7.00. The company has a fifty day moving average of $1.56 and a 200-day moving average of $2.49.

Insider Transactions at OS Therapies

In other OS Therapies news, major shareholder Shalom Auerbach sold 50,012 shares of the company’s stock in a transaction dated Wednesday, April 9th. The shares were sold at an average price of $1.35, for a total value of $67,516.20. Following the sale, the insider now owns 2,756,199 shares of the company’s stock, valued at $3,720,868.65. This represents a 1.78 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 13.80% of the company’s stock.

Institutional Trading of OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new position in shares of OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,045 shares of the company’s stock, valued at approximately $28,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.